Stanford Researchers cite BioPharm Laboratories High Purity Thrombin
February 10, 2022
More accolades for BioUtah member BioPharm Laboratories – another journal article from the Journal of Biological Chemistry cites the use of BioPharm’s High Purity Thrombin being used to cleave protein in their protein purification process. This time from researchers at Stanford University.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a genetic trait that can cause hemolytic anemia. To date, over 150 non-synonymous mutations have been identified in G6PD, with pathogenic mutations clustering near the dimer and/or tetramer interface and the allosteric NADP+-binding site. BioPharm has identified a small molecule which activates G6PD variants by stabilizing the allosteric NADP+ and dimer complex, suggesting therapeutics that target these regions may improve structural defects.
Recent News
- Rep. Celeste Maloy Tours BIOS, Neurotech Innovation
- U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome
- Sera Prognostics Appoints Scott Gleason CFO
- Merit Medical Announces Global Operations Leadership Transition
- Utah Life Sciences Innovation Caucus Breakfast
- Curavit Expands Clinical Research Capabilities with Acquisition of Lindus Health CRO Assets, Accelerating Global Trial Execution for Life Science Sponsors
